Berlin, August 25, 2014 - Bayer HealthCare announced today that results from the Phase IIIb exploratory X-VeRT study investigating the oral Factor Xa inhibitor Xarelto® (rivaroxaban) in patients with non-valvular atrial fibrillation (AF) undergoing elective cardioversion will be presented in a Hot Line Session during the upcoming ESC Congress 2014 in Barcelona, Spain, August 30 - September 3, 2014. The X-VeRT study is the first prospective trial comparing the benefit-risk profile of a novel oral anticoagulant with dose-adjusted warfarin in AF patients undergoing elective cardioversion.

• The X-VeRT Trial: A comparison of oral rivaroxaban once daily with dose-adjusted Vitamin K Antagonists in patients with non-valvular atrial fibrillation undergoing elective cardioversion
o Hot Line Session: Coronary artery disease and atrial fibrillation
o Tuesday, September 2, 2014, 11:18 - 11:36am, Barcelona - Central Village
o Note: Hot Line abstract under embargo until time of the Hot Line V Coronary artery disease and atrial fibrillation press conference on Tuesday, September 2, 2014 at 8:00am

Oral and Poster Presentations on Rivaroxaban in Arterial Blood Clot Management
Sub-analyses from ROCKET AF and ATLAS ACS 2-TIMI 51 studies providing further insights into the clinical utility of rivaroxaban across arterial thromboembolic conditions include the following:
• Higher risk of death and stroke in patients with persistent versus paroxysmal atrial fibrillation: results from the ROCKET AF trial
o Oral Session: Atrial Fibrillation: How to improve prognosis?
o Tuesday, September 2, 2014, 8:30 - 8:45am, Vilnius - Village 9
• Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial
o Oral Session: Atrial Fibrillation: How to improve prognosis?
o Tuesday, September 2, 2014, 9:00 - 9:15am, Vilnius - Village 9
• Patients with native aortic stenosis represent a high-risk subgroup in non-valvular atrial fibrillation - Results from ROCKET AF
o Oral Session: Risk assessment in atrial fibrillation: what really matters?
o Tuesday, September 2, 2014, 3:00 - 3:15pm, Vilnius - Village 9
• Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation: insights from the ATLAS ACS 2-TIMI 51 trial
o Poster Session 6: Thrombosis and anticoagulation - II
o Tuesday, September 2, 2014, 8:30am - 12:30pm, Poster Area - Central Village

Results from the Phase IIa X-PLORER study on once-daily rivaroxaban compared to unfractionated heparin after elective PCI in patients with coronary artery disease (CAD) will also be presented.
• Rivaroxaban in elective percutaneous coronary intervention (PCI) to treat stable coronary artery disease
o Poster Session 6: Thrombosis and anticoagulation - II
o Tuesday, September 2, 2014, 8:30am - 12:30pm, Poster Area - Central Village

Rivaroxaban is the most studied and widely published novel oral anticoagulant. The extensive ongoing rivaroxaban programme will include more than 260,000 patients in both clinical trials and real world settings.

Poster Presentations Offering Real World Patient Insights
Independently, the Thrombosis Research Institute (TRI) will present new data from GARFIELD AF (Global Anticoagulant Registry in the FIELD), an observational, multicentre Registry of men and women with newly diagnosed AF and one or more additional investigator determined risk factors for stroke. The GARFIELD AF Registry is an academic research initiative, led by the TRI and a multi-disciplinary Steering Committee, supported by an unrestricted educational grant from Bayer Pharma AG.

• International normalized ratio control and 1-year outcomes in patients with newly diagnosed atrial fibrillation: the GARFIELD Registry
o Poster Session 7: Stroke and anticoagulants in atrial fibrillation
o Tuesday September 2, 2014, 2:00 - 6:00pm, Poster Area - Central Village
• Is cardiovascular death a primary driver of mortality in higher age groups of patients with non-valvular atrial fibrillation? Results from the GARFIELD Registry
o Poster Session 3: Clinical outcomes in atrial fibrillation I
o Sunday August 31, 2014, 2:00 - 6:00pm, Poster Area - Central Village
• 'Truly low-risk' patients with newly diagnosed non-valvular atrial fibrillation at risk of stroke: 1-year outcomes from the GARFIELD Registry
o Poster Session 7: Anticoagulants and stroke in atrial fibrillation
o Tuesday September 2, 2014, 2:00 - 6:00, Poster Area - Central Village

About Xarelto® (Rivaroxaban)
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. Xarelto is approved for five indications across seven distinct areas of use, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel oral anticoagulant:

• The prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (AF) with one or more risk factors

• The treatment of deep vein thrombosis (DVT) in adults

• The treatment of pulmonary embolism (PE) in adults

• The prevention of recurrent DVT and PE in adults

• The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip replacement surgery

• The prevention of VTE in adult patients undergoing elective knee replacement surgery

• The prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) after Acute Coronary Syndrome in adult patients with elevated cardiac biomarkers when co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications Xarelto is approved in more than 125 countries.

Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company).

Anticoagulant medicines are potent therapies used to prevent or treat serious illnesses and potentially life-threatening conditions. Before initiating therapy with anticoagulant medicines, physicians should carefully assess the benefit and risk for the individual patient.

Responsible use of Xarelto is a very high priority for Bayer, and the company has developed a Prescribers Guide for physicians and a Xarelto Patient Card for patients to support best practice.

To learn more, please visit https://prescribe.xarelto.com
To learn more about thrombosis, please visit www.thrombosisadviser.com
To learn more about Xarelto, please visit www.xarelto.com

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at www.healthcare.bayer.com.

Our online press service is just a click away: press.healthcare.bayer.com

Find more information at www.bayerpharma.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

distributed by